Cabin Air Sensor Solutions Ltd, (CASS) announced today that they had successfully completed their 9-month compound sensing work package adding Ethanol, Ammonia, Acetone, Toluene, Tricresyl Phosphate & Carbon Monoxide to their compound detection capability.
Operations Director Mark Gilmore said, “In May 2022 the UK’s National Physical Laboratory, verified the sensor’s ability to detect Tributyl Phosphate in real-time which was key in our development of the sensing technology pathway. Using the lessons learned whilst working on the TBP coating has enabled us to rapidly open a huge opportunity for the company by increasing our sensing capability to cover 5 further compounds, and a gas”.
CASS also announced that their Japanese Patent Application had been granted, and that further grants are pending final investigations.
David Newman, CASS CEO said, “It has been an extremely difficult journey for a small start-up company to take this completely original Idea from Concept, though to Prototype and then, to Portable Handheld Sensor, but with the support of our private & corporate investors, together with our scientific team, we have finally made it, and are incredibly proud of the achievement”.
The bipartisan Federal Aviation Administration reauthorization is a big win for travelers, the aviation workforce, and our economy. It will expand critical protections for air travelers, strengthen safety standards, and support pilots, flight attendants, and air traffic controllers. It also builds on my Administration’s efforts to improve the travel experience for airline passengers, affirming the Department… Continue reading Statement from President Joe Biden After Signing FAA Reauthorization Act
Read MorePublished on: 25 Apr 2024, under Press Releases Cambridge, UK, April 25, 2024: Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced it has secured funding from the Bill & Melinda Gates Foundation (“the Gates Foundation” or “the foundation”). The funding is comprised of a… Continue reading Owlstone Medical Secures $6.5 Million to Support Development of Breath-based Diagnostics for Infectious Disease
Read MorePublished on: 9 Nov 2023, under Science & Research Cambridge, UK, November 9, 2023: Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced the results of a peer-reviewed study in the journal Biomedicines – ‘Exogenous Volatile Organic Compound (EVOC®) Breath Testing Maximizes Classification Performance for Subjects with Cirrhosis… Continue reading Owlstone Medical Publishes Exciting Liver Data on the use of an EVOC® Probe for the Early Detection of Cirrhosis
Read More
Cabin Air Sensor Solutions Ltd, (CASS) announced today that they had successfully completed their 9-month compound sensing work package adding Ethanol, Ammonia, Acetone, Toluene, Tricresyl Phosphate & Carbon Monoxide to their compound detection capability.
Read More